Agenus Inc. (AGEN)

Market Cap	66.39M
Revenue (ttm)	160.43M
Net Income (ttm)	-227.86M
Shares Out	23.46M
EPS (ttm)	-11.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	692,308
Open	2.750
Previous Close	2.760
Day's Range	2.672 - 2.910
52-Week Range	2.500 - 19.690
Beta	1.24
Analysts	Buy
Price Target	10.50 (+271.03%)
Earnings Date	Nov 12, 2024

About AGEN

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2000
• Employees: 389
• Stock Exchange: NASDAQ
• Ticker Symbol: AGEN
• Website: https://www.agenusbio.com

Financial Performance

In 2023, Agenus's revenue was $156.31 million, an increase of 59.47% compared to the previous year's $98.02 million. Losses were -$245.97 million, 11.7% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for AGEN stock is "Buy." The 12-month stock price forecast is $10.5, which is an increase of 271.03% from the latest price.

Price Target

$10.5

(271.03% upside)

Analyst Consensus: Buy